What makes our Scientific Advisory Board unique is that each member is an active user of our medical devices (MDs). Their feedback, based on real-life experience, is essential in adapting our technology to the needs of the field. We would like to express our gratitude to the distinguished members of our Scientific Advisory Board:
Discussion of the regulatory aspects of our DM and the implementation of the ISO 13485 Quality Management System.
Presentation of the results of the PIXAIRE-I clinical study on WoundTrack-II, highlighting interesting results concerning dimensional and wound content analysis. The technical file for CE marking of our class IIa DM has been submitted to the notified body.
Reflection on the optimal frequency of consultations for different types of chronic wounds, and the potential impact of telemonitoring on reducing this frequency.
To obtain reimbursement for remote monitoring of chronic wounds, it is essential to develop an automatic alert system. Members shared their expert opinions on the most relevant indicators and alerts, particularly in terms of infection and healing.
The recommendations of the Scientific Advisory Board are fundamental elements in the continuous improvement of the solutions developed by Pixacare. Their advice, based on practical experience, serves as a guide to refine and evolve our products, ensuring that our DMs remain at the cutting edge of technology and meet the real needs of healthcare professionals.
In conclusion, this second Pixacare scientific board was a key step in our innovation process. We are at the dawn of a revolution in chronic wound management, with Pixacare at the forefront of this transformation. The fruitful exchanges and future prospects that have ensued testify to our commitment to transforming healthcare through our solutions.
